

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**203168Orig1s000**

***Trade Name:*** Prolensa Ophthalmic Solution 0.07%

***Generic Name:*** Bromfenac Ophthalmic Solution

***Sponsor:*** Bausch & Lomb, Inc.

***Approval Date:*** 04/05/2013

***Indications:*** Treatment of Postoperative Inflammation and Reduction of Ocular Pain in Patients Who Have Undergone Cataract Surgery.

# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*  
**203168Orig1s000**

## CONTENTS

### Reviews / Information Included in this NDA Review.

|   |          |
|---|----------|
| <b>Approval Letter</b>                                  | <b>X</b> |
| <b>Other Action Letters</b>                             |          |
| <b>Labeling</b>   | <b>X</b> |
| <b>REMS</b>   |          |
| <b>Summary Review</b>                                   | <b>X</b> |
| <b>Officer/Employee List</b>                            | <b>X</b> |
| <b>Office Director Memo</b>                             | <b>X</b> |
| <b>Cross Discipline Team Leader Review</b>              | <b>X</b> |
| <b>Medical Review(s)</b>                                | <b>X</b> |
| <b>Chemistry Review(s)</b>                              | <b>X</b> |
| <b>Environmental Assessment</b>                         |          |
| <b>Pharmacology Review(s)</b>                           | <b>X</b> |
| <b>Statistical Review(s)</b>                            | <b>X</b> |
| <b>Microbiology Review(s)</b>                           | <b>X</b> |
| <b>Clinical Pharmacology/Biopharmaceutics Review(s)</b> | <b>X</b> |
| <b>Other Reviews</b>                                    | <b>X</b> |
| <b>Risk Assessment and Risk Mitigation Review(s)</b>    |          |
| <b>Proprietary Name Review(s)</b>                       | <b>X</b> |
| <b>Administrative/Correspondence Document(s)</b>        | <b>X</b> |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**203168Orig1s000**

**APPROVAL LETTER**



NDA 203168

**NDA APPROVAL**

Bausch & Lomb, Incorporated  
Attention: Paul Nowacki  
Director, Regulatory Affairs  
50 Technology Drive  
Irvine, CA 92618

Dear Mr. Nowacki:

Please refer to your New Drug Application (NDA) dated June 6, 2012, received June 7, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prolensa (bromfenac ophthalmic solution) 0.07%.

We acknowledge receipt of your amendments dated August 20 and 31, September 8, 12, and 20, October 9, November 16, and December 19 and 20, 2012, and March 12, 18, and April 3, 2013.

This new drug application provides for the use of Prolensa (bromfenac ophthalmic solution) 0.07% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed text for the package insert. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND IMMEDIATE-CONTAINER LABELS**

Submit final printed carton and immediate-container labels that are identical to the enclosed carton and immediate-container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 203168.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

With the next scheduled printing, the cartons should be revised to include a more precise description of the active (i.e., bromfenac sodium sesquihydrate 0.0805%) consistent with the package insert.

## **MARKET PACKAGE**

Please submit one market package of the drug product when it is available to the following address:

Michael Puglisi  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 6162  
10903 New Hampshire Avenue  
Silver Spring, Maryland  
*Use zip code **20903** if shipping via United States Postal Service (USPS).*  
*Use zip code **20993** if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).*

## **PEDIATRIC ASSESSMENT**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because your application does not include a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration, this requirement is inapplicable.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Puglisi, Regulatory Project Manager, at (301) 796-0791.

Sincerely,

*{See appended electronic signature page}*

Renata Albrecht, MD  
Director  
Division of Transplant and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosures:

Content of Labeling  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

RENATA ALBRECHT  
04/05/2013